Pegcetacoplan, the first C3 inhibitor for the treatment of PNH, was recently approved by the FDA and EMA.21, –23 New treatment strategies will aim to address some of the challenges of current therapies (e.g. EVH-mediated anemia, patient convenience, and HRQoL).98 Future PNH therapy should seek to maintain terminal complement suppression and improve HRQoL in this chronic and potentially devastating disease. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.